These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 2682129)

  • 1. Pharmacokinetics and toxicity of bismuth compounds.
    Slikkerveer A; de Wolff FA
    Med Toxicol Adverse Drug Exp; 1989; 4(5):303-23. PubMed ID: 2682129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bismuth toxicity in man II. Review of bismuth blood and urine levels in patients after administration of therapeutic bismuth formulations in relation to the problem of bismuth toxicity in man.
    Serfontein WJ; Mekel R
    Res Commun Chem Pathol Pharmacol; 1979 Nov; 26(2):391-411. PubMed ID: 392661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate.
    Froomes PR; Wan AT; Keech AC; McNeil JJ; McLean AJ
    Eur J Clin Pharmacol; 1989; 37(5):533-6. PubMed ID: 2598996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alleviation of cisplatin toxicity by high-dose bismuth subnitrate and pharmacokinetics of bismuth subnitrate and cisplatin].
    Morikawa T; Kawamura E; Komiyama T; Imura N
    Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1138-45. PubMed ID: 2398299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Iatrogenic myoclonic encephalopathies caused by bismuth salts].
    Loiseau P; Henry P; Jallon P; Legroux M
    J Neurol Sci; 1976 Feb; 27(2):133-43. PubMed ID: 1249582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total allowable concentrations of monomeric inorganic aluminum and hydrated aluminum silicates in drinking water.
    Willhite CC; Ball GL; McLellan CJ
    Crit Rev Toxicol; 2012 May; 42(5):358-442. PubMed ID: 22512666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Absorption and renal elimination of bismuth from 6 different bismuth salts after a single dosage].
    Heckers H; Mannl MR; Muskat E; Stelz A; Bödeker RH
    Z Gastroenterol; 1994 Jul; 32(7):375-81. PubMed ID: 7975772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bismuth therapy in gastrointestinal diseases.
    Gorbach SL
    Gastroenterology; 1990 Sep; 99(3):863-75. PubMed ID: 2199292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of bismuth from 205Bi-labelled pharmaceutical oral Bi-preparations in rats.
    Dresow B; Nielsen P; Fischer R; Wendel J; Gabbe EE; Heinrich HC
    Arch Toxicol; 1991; 65(8):646-50. PubMed ID: 1747063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of bismuth in the rat after oral dosing with ranitidine bismuth citrate and bismuth subcitrate.
    Canena J; Reis J; Pinto AS; Santos AM; Leitão J; Pinheiro T; Quina MG
    J Pharm Pharmacol; 1998 Mar; 50(3):279-83. PubMed ID: 9600719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and tissue distribution of bismuth in normal and cirrhotic rats.
    Luppino MA; McLean AJ
    Analyst; 1995 Mar; 120(3):883-6. PubMed ID: 7741247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A method of cisplatin administration with the aid of high-dose bismuth subnitrate, and their pharmacokinetics].
    Morikawa T; Kawamura E
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1094-8. PubMed ID: 2730014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encephalopathy associated with bismuth subgallate therapy.
    Friedland RP; Lerner AJ; Hedera P; Brass EP
    Clin Neuropharmacol; 1993 Apr; 16(2):173-6. PubMed ID: 8477413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of meals on resorption of bismuth from an oral bismuth gallate/bismuth nitrate preparation].
    Leonhardt H; Klotz U
    Med Klin (Munich); 1991 Apr; 86(4):194-7. PubMed ID: 2056984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of plasma bismuth levels after oral dosing with basic bismuth carbonate or tripotassium dicitrato bismuthate.
    Madaus S; Schulte-Frohlinde E; Scherer C; Kämmereit A; Schusdziarra V; Classen M
    Aliment Pharmacol Ther; 1992 Apr; 6(2):241-9. PubMed ID: 1288519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of bismuth toxicity by l-cysteine.
    Krari N; Mauras Y; Allain
    Res Commun Mol Pathol Pharmacol; 1995 Sep; 89(3):357-64. PubMed ID: 8680804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds.
    Nwokolo CU; Prewett EJ; Sawyerr AM; Hudson M; Pounder RE
    Gastroenterology; 1991 Oct; 101(4):889-94. PubMed ID: 1889712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of bismuth in the brain after intraperitoneal dosing of bismuth subnitrate in mice: implications for routes of entry of xenobiotic metals into the brain.
    Ross JF; Switzer RC; Poston MR; Lawhorn GT
    Brain Res; 1996 Jul; 725(2):137-54. PubMed ID: 8836520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a therapeutic procedure for bismuth intoxication with chelating agents.
    Slikkerveer A; Jong HB; Helmich RB; de Wolff FA
    J Lab Clin Med; 1992 May; 119(5):529-37. PubMed ID: 1583409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inorganic bismuth(III) compounds in the therapy.
    Wesolowski M
    Arzneimittelforschung; 1978; 28(3):372-8. PubMed ID: 350231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.